HIV/AIDS Vaccine: Development, Doses, Administration, and Global Impact
Introduction to HIV/AIDS
HIV (Human Immunodeficiency Virus) is a virus that attacks the body’s immune system, specifically the CD4 cells (T cells), which help the immune system fight off infections. If left untreated, HIV can lead to the disease AIDS (Acquired Immunodeficiency Syndrome). Since its discovery in the early 1980s, HIV/AIDS has claimed millions of lives worldwide, making it one of the most significant public health challenges.
While antiretroviral therapy (ART) has transformed HIV from a fatal condition to a manageable chronic disease, the ultimate goal has been to develop a preventive vaccine that can stop the transmission of HIV.
Why an HIV Vaccine is Crucial
Vaccines are among the most effective tools in controlling infectious diseases. For HIV, a vaccine would:
Prevent new infections
• Help control the epidemic globally
• Reduce the burden of treatment and healthcare costs
Provide long-lasting immunity
Protect vulnerable populations including adolescents and young adults
Challenges in HIV Vaccine Development
Despite extensive research, developing an effective HIV vaccine has been uniquely difficult due to:
• High mutation rate of HIV
• Diverse strains and subtypes of HIV worldwide
• Ability of the virus to hide in dormant cells (viral latency)
• Lack of natural immunity in individuals who recover from exposure
• Complex immune response needed to neutralize the virus
Who First Developed the HIV Vaccine?
The journey of HIV vaccine development began in the late 1980s. Some notable milestones include:
1. AIDSVAX by VaxGen (1998–2003)
• First HIV vaccine candidate to enter Phase III clinical trials.
• Composed of gp120, a protein on the surface of the virus.
• Results: The vaccine was safe but did not offer significant protection.
2. RV144 Trial (Thailand, 2003–2009)
• First HIV vaccine trial to show modest efficacy (31%).
• A combination of ALVAC-HIV (canarypox vector) and AIDSVAX B/E.
• Conducted by the U.S. Army, Thai Ministry of Health, and other collaborators.
• Led to renewed hope and further investigations into HIV vaccine design.
3. Recent Advances (2020s)
• Moderna, NIH, IAVI, and Bill & Melinda Gates Foundation have been instrumental in developing mRNA-based HIV vaccine candidates, building on the success of COVID-19 vaccine platforms.
• Ongoing trials focus on germline targeting, broadly neutralizing antibodies (bNAbs), and mRNA technology.
Types of HIV Vaccine Candidates
1. Preventive (Prophylactic) Vaccines
Designed to prevent infection in people who are HIV-negative.
2. Therapeutic Vaccines
Aim to improve the immune response in people already infected with HIV.
3. Vector-based Vaccines
Use a harmless virus to deliver HIV genes into the body to stimulate an immune response.
4. DNA or mRNA Vaccines
Teach the body’s cells to produce HIV proteins to trigger immunity (e.g., Moderna’s mRNA-based HIV vaccines).
Approved HIV Vaccine?
As of August 2025, no HIV vaccine has been officially approved for widespread public use. However, multiple clinical trials are ongoing, and promising candidates are in advanced stages of testing.
HIV Vaccine Doses and Schedule
Since there is no officially approved HIV vaccine yet, the dose and schedule depend on the candidate being tested in clinical trials. However, some general patterns from past and current trials include:
1. RV144 Schedule
• A total of six doses over six months:
• Four doses of ALVAC-HIV at 0, 1, 3, and 6 months.
• Two booster doses of AIDSVAX B/E at 3 and 6 months.
2. Moderna’s mRNA Vaccine Schedule
• Typically involves two doses, spaced 4–8 weeks apart.
• May require booster shots to enhance or prolong immunity.
• Each vaccine trial has its own protocol, based on the vaccine design and immune response goals.
Route of Administration
Most HIV vaccines under investigation are administered via:
Intramuscular (IM) injection
• This route is preferred because it ensures:
• Efficient delivery of the antigen to immune cells
• Stronger and longer-lasting immune responses
• Compatibility with existing vaccination infrastructure
Injection Sites
• HIV vaccines are typically injected into:
• Deltoid muscle (upper arm)
• Alternative sites in some cases: thigh or gluteal muscles
• The deltoid muscle is most commonly used due to:
Easy access
• Adequate muscle mass for adults and adolescents
• Fewer side effects compared to other areas
Who Should Get the HIV Vaccine?
Once an HIV vaccine becomes approved, it is expected to be recommended for:
• Adolescents and young adults (ages 9–26)
• Individuals in high-risk groups:
• Men who have sex with men (MSM)
• People who inject drugs (PWID)
Sex workers
• Individuals with HIV-positive partners
• General population in regions with high HIV prevalence
Potential Side Effects of HIV Vaccines
Most vaccine trials report mild to moderate side effects, including:
• Pain at the injection site
• Fatigue
• Headache
• Muscle aches
• Low-grade fever
Serious adverse effects are rare, and all vaccine candidates are subject to rigorous testing for safety and efficacy.
Current HIV Vaccine Trials (2025)
1. Moderna and NIH (mRNA-1644 & mRNA-1574)
• Uses mRNA technology like COVID-19 vaccines
• Focuses on stimulating broadly neutralizing antibodies (bNAbs)
• Phase 1 trials showed promising immune responses
2. IAVI G002 Trial
• Uses germline-targeting strategy to initiate immune response
• Early success in triggering desired B-cell activity
3. PrEPVacc Trial
• Combines HIV vaccine and pre-exposure prophylaxis (PrEP)
• Being conducted in African countries including Uganda and Tanzania
• Global Impact of an HIV Vaccine
• An effective HIV vaccine could:
Prevent millions of new infections
Reduce the spread of HIV/AIDS, especially in high-burden regions like sub-Saharan Africa
Lower the cost of lifelong ART
• Empower at-risk populations with additional protection
• Transform public health systems, as seen with polio and smallpox eradication efforts
• Comparison: HIV Vaccine vs. HIV Treatment
Feature HIV Vaccine HIV Treatment (ART)
• Purpose Prevent infection Suppress virus in infected person
• Timing Before exposure After infection
• Doses Few doses (once developed) Daily for life
• Route Intramuscular injection Oral medication
• Impact on transmission Can stop transmission entirely Reduces but doesn’t eliminate risk
• Accessibility Still in development Widely available
Future of HIV Vaccine Research
• The future of HIV vaccine research is bright, thanks to:
• Advances in genomics and immunology
• Use of artificial intelligence (AI) and big data to model immune responses
Lessons from COVID-19 vaccine development
• Global collaboration between governments, academia, and private sector
How You Can Support HIV Vaccine Development
• Participate in clinical trials (if eligible)
• Donate to HIV research organizations
• Spread awareness about prevention and education
• Advocate for global funding and policy support
Conclusion
The development of an HIV/AIDS vaccine is a monumental scientific pursuit with the potential to end one of the most devastating pandemics in human history. Though a fully approved vaccine is not yet available, the progress made—especially with mRNA technology and innovative immunological approaches—is more promising than ever before.
With continued investment, global collaboration, and public engagement, the HIV vaccine is no longer a distant dream but a foreseeable reality that could save millions of lives and bring us closer to an AIDS-free generation.
I hope that you liked this article.
Thanks!! 🙏 😊
Writer: Vandita Singh, Lucknow (GS India Nursing Group)